Maria Jesus
Peñarrubia Ponce
Hospital Miguel Servet
Zaragoza, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Miguel Servet (11)
2021
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
2016
-
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302
2015
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
-
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211
2012
-
Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement
European Journal of Haematology, Vol. 89, Núm. 1, pp. 37-41
2010
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Blood, Vol. 114, Núm. 1, pp. 148-152
2008
-
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Haematologica, Vol. 93, Núm. 12, pp. 1797-1805
2003
-
A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses
Annals of Hematology, Vol. 82, Núm. 12, pp. 750-758